Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of pirfenidone derivative to pharmaceuticals

A drug and pharmacy technology, applied in anti-tumor drugs, drug combinations, pharmaceutical formulations, etc., can solve the problems of no anti-fibrotic drugs, anti-tumor drugs, poor anti-fibrotic activity, etc., and achieve the effect of good industrialization prospects.

Inactive Publication Date: 2016-08-24
SICHUAN UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Anti-fibrotic drugs refer to the medicines for the treatment and / or prevention of fibrotic diseases, such as: pirfenidone (pharmaceutical product listed on the market), however, the inhibitory rate of this compound to fibroblast proliferation can only reach 8.15%, anti-fibrotic poor activity
[0004] At present, there is no relevant report that the compound represented by formula I of the present invention or its pharmaceutically acceptable salt, crystal form, hydrate or solvate is used for the preparation of anti-fibrosis drugs and / or anti-tumor drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of pirfenidone derivative to pharmaceuticals
  • Application of pirfenidone derivative to pharmaceuticals
  • Application of pirfenidone derivative to pharmaceuticals

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Embodiment 1, the synthesis of compound 5b of the present invention

[0047] synthetic route:

[0048]

[0049] 1. Synthesis of compound 3 (5-methyl-2-(1H)-pyridone)

[0050] First add 3.40mL of 50% sulfuric acid (v / v) to a 25mL reaction flask, then add 1.00g (10mmol) of 2-amino-5-picoline (compound 1), cool to below 10°C in an ice-salt bath, and stir for several After 10 minutes, the reaction solution turned milky white; then slowly added dropwise 1.72g (25mmol) NaNO 2 with 3mL H 2 The mixed solution composed of O has brown-yellow gas with pungent odor during the dropwise addition process. After the addition, the reaction solution turns light yellow. Use 10% dilute sulfuric acid to adjust the pH to 7-8, reflux and stir for about 20 minutes, and spin Most of the water was removed, an appropriate amount of 300 mesh silica gel was added thereto, spin-dried, poured into a glass sand core funnel, rinsed with ethyl acetate and suction-filtered, and the filtrate was spi...

Embodiment 2

[0059] Embodiment 2, the synthesis of compound 5c of the present invention

[0060] According to the method similar to Example 1, in step 3, ethylenediamine was used as a raw material to prepare compound 5c, and the single-step yield of step 3 was 69%.

[0061]

[0062] Compound 5c: 1-(4-(4,5-dihydro-1H-imidazol-2-yl)phenyl)-5-methylpyridin-2(1H)-one, yellow solid, m.p.252-254°C;

[0063] 1 H NMR (400MHz, DMSO) δ8.01 (d, J = 8.5Hz, 2H), 7.68 (d, J = 8.5Hz, 2H), 7.55–7.31 (m, 2H), 6.45 (d, J = 9.3Hz ,1H),4.02–3.25(m,4H),2.05(s,3H),1.86(dd,J=12.6,9.6Hz,1H);

[0064] 13 C NMR (101MHz, DMSO) δ164.04, 160.29, 144.87, 143.66, 135.37, 129.01, 127.50, 125.22, 123.22, 120.32, 114.84, 69.80, 45.61, 16.42;

[0065] HRMS (ESI) calcd for C 15 h 15 N 3 O[M+H] + 254.1294, found 254.1289.

Embodiment 3

[0066] Embodiment 3, the synthesis of compound 5d of the present invention

[0067] According to the method similar to Example 1, using 1,3-propylenediamine as raw material in step 3, compound 5d was prepared, and the single-step yield of step 3 was 54%.

[0068]

[0069] Compound 5d: 1-(4-(1,4,5,6-tetrahydropyrimidin-2-yl)phenyl)-5-methylpyridin-2(1H)-one, yellow solid, m.p.265-267℃ ;

[0070] 1 H NMR (400MHz, DMSO) δ7.83 (d, J = 8.5Hz, 2H), 7.68 (d, J = 8.5Hz, 2H), 7.51–7.40 (m, 2H), 6.45 (d, J = 9.3Hz ,1H),3.51(m,6H),2.93(dd,J=14.7,7.4Hz,1H),2.05(d,J=13.5Hz,3H);

[0071] 13 C NMR (101MHz, DMSO) δ160.21, 158.66, 144.51, 143.61, 135.29, 128.51, 127.95, 127.39, 120.27, 114.62, 45.76, 17.60, 16.37, 11.06;

[0072] HRMS (ESI) calcd for C 16 h 17 N 3 O[M+H] + 268.1451, found 268.1449.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a compound shown in the formula I or pharmaceutically acceptable salt or crystal forms or aquo-complex or solvate of the compound to preparation of anti-fibrosis drugs and / or antitumor drugs. In the formula I, R1, R2, R3, R4 and R5 are selected from H, halogen, hydroxyl, nitryl and carbonyl or C1-C8 alkyl respectively or simultaneously; R6 and R7 are selected from H or C1-C8 alkyl respectively or simultaneously, and R6 and R7 are connected to form a five-membered ring or six-membered ring containing 3-17 carbon atoms. According to the application of the new compound shown in the formula I or the pharmaceutically acceptable salt or crystal forms or aquo-complex or solvate of the compound to preparation of the anti-fibrosis drugs and / or the antitumor drugs, compared with pirfenidone, the new compound has a ring structure different from that of pirfenidone, and the anti-fibrosis activity of the new compound is remarkably better than that of pirfenidone, so that the new compound has good industrial prospects. (Please see the description for the formula I.).

Description

technical field [0001] The invention relates to the application of pirfenidone derivatives in pharmacy. Background technique [0002] Fibrosis refers to the pathological process of reduction or necrosis of parenchymal cells in patients' organs, increase of extracellular matrix in tissues and diffuse excessive deposition caused by various pathogenic factors. Continuous progress can lead to destruction of organ structure and functional decline, until failure. Fibrosis can occur in many organs, and the most common clinical fibrosis mainly includes: (1) pulmonary fibrosis; (2) liver fibrosis; (3) cardiac fibrosis; (4) renal fibrosis and (5) Fibrosis of the pancreas; in addition, fibrosis of the eye, blood vessels, and nervous system may also occur. [0003] Anti-fibrotic drugs refer to the medicines for the treatment and / or prevention of fibrotic diseases, such as: pirfenidone (pharmaceutical product listed on the market), however, the inhibitory rate of this compound to fibrob...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4439A61K31/506A61P35/00A61P11/00A61P1/16A61P1/18A61P9/00A61P13/12A61P27/02A61P15/00
CPCA61K31/4439A61K31/506
Inventor 尹述凡黎勇曹婷婷杨子耀
Owner SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com